Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. develops enzyme-based solutions for therapeutics manufacturing, using its CodeEvolver technology to discover and improve high-performance enzymes. Company news commonly covers financial results, guidance, cash-runway commentary, and business updates tied to small molecule pharmaceutical biocatalysis, nucleic acid synthesis, and the ECO Synthesis manufacturing platform for enzymatic RNAi and siRNA production.
Recurring developments include partner and evaluation agreements, technology-transfer activity, quality-system and manufacturing-suite updates, conference data on ECO Synthesis capabilities such as phosphorothioate stereochemistry and ligation efficiency, and portfolio updates for enzymes used in branded pharmaceutical products.
Codexis (NASDAQ: CDXS) announced it will report Q2 2026 financial results on Tuesday, August 11, 2026, after the market close. Management will host a conference call and webcast at 4:30 p.m. Eastern Time to review results and provide a business update.
Investors can access the live webcast via the Codexis Investor Relations website, with an archive available for 90 days. The live call is available at 877-705-2976 (domestic) or 201-689-8798 (international). A 48-hour telephone replay will be offered at 877-660-6853 (domestic) or 201-612-7415 (international), access ID 13726635.
Codexis (Nasdaq: CDXS) priced an underwritten public offering of 16,666,667 common shares at $1.50 per share, with expected net proceeds of approximately $23.1 million after underwriting discounts, commissions and estimated expenses. The transaction is expected to close on or about July 27, 2026, subject to customary conditions.
According to Codexis, underwriters have a 30-day option to buy up to an additional 2,500,000 shares at the same public price, less underwriting discounts and commissions. The company plans to use proceeds for working capital and other general corporate purposes, including research, development and business activities.
Codexis (Nasdaq: CDXS) has commenced an underwritten public offering of its common stock, with all shares to be sold by the company. Codexis also expects to grant underwriters a 30-day option to purchase up to an additional 15% of the offered shares on the same terms.
The size and terms of the offering remain subject to market and other conditions, and completion is not assured. According to Codexis, net proceeds are intended for working capital and general corporate purposes, including research, development and business activities. Piper Sandler and Cantor are joint bookrunning managers, with Craig-Hallum as co-manager. The offering uses an SEC registration statement declared effective on May 14, 2024 and will be made via prospectus and prospectus supplement.
Codexis (NASDAQ:CDXS) showcased advances in RNA therapeutic manufacturing at TIDES USA 2026, highlighting its ECO Synthesis platform for siRNA production with precise phosphorothioate stereochemistry control. Stereochemical control is described as increasingly important for potency, product quality, and potential new dosage forms.
The company also reported the ability to start enzymatic RNA synthesis from a single nucleotide, removing the need for starter oligonucleotides, and shared sustainability data showing over 50% lower global warming potential and about 2.7-fold lower impact on an input materials basis versus conventional methods.
Codexis (NASDAQ: CDXS) reported Q1 2026 revenue of $15.2 million and reiterated full‑year guidance of $72–$76 million. Product gross margin was 71%; net loss narrowed to $8.7 million ($0.10/share). Cash and short‑term investments totaled $65.1 million, which the company says funds operations through end of 2027.
The company highlighted ECO Synthesis® platform progress, three upcoming TIDES presentations on siRNA stereochemistry and ligation, a 50g siRNA supply agreement for pre‑IND studies, ISO 9001 certification, and plans for an ECO GMP Manufacturing Center.
Codexis (NASDAQ: CDXS) will present RNA manufacturing advances at TIDES USA, May 11–14 in Boston. Presentations cover ECO Synthesis® platform results on phosphorothioate stereochemistry control, ligation efficiency, process performance, and sustainability. Codexis will host a panel and maintain a booth (821) during the conference.
Codexis (NASDAQ: CDXS) will report Q1 2026 financial results on May 7, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update. The live webcast will be archived for 90 days; telephone replay available for 48 hours (Access ID #13726635).
Codexis (NASDAQ: CDXS) reported fourth-quarter revenue of $38.9M and fiscal 2025 total revenue of $70.4M. The company ended 2025 with $78.2M in cash and expects runway through 2027. Fiscal 2025 saw product gross margin of 64% and a net loss of $44.0M.
Q4 growth was driven by a $37.8M Technology Transfer Agreement with Merck and momentum in ECO Synthesis commercial engagements; the company provided 2026 revenue guidance of $72M–$76M.
Codexis (NASDAQ: CDXS) announced on March 4, 2026 an agreement to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis manufacturing platform to support a partner's preclinical cardiovascular program.
The engagement is presented as a demonstration of the platform's ability to produce material beyond early research volumes and as a potential pathway to further scale-up and commercial manufacturing, subject to program advancement.
Codexis (NASDAQ: CDXS) will report fourth quarter and fiscal year 2025 results on Wednesday, March 11, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update.
The live webcast will be available on the Codexis Investor Relations website and archived for 90 days; a telephone replay will be available for 48 hours.